Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients

Abstract

<b><i>Background and Aims:</i></b> Although pancreatic cancers are common in older age-groups, the prognosis remains poor due to limited studies on treatment approaches and outcomes in a given population. We aimed to examine treatment patterns and their outcomes in older patients with metastatic pancreatic cancer in a real-world context. <b><i>Materials and Methods:</i></b> We conducted a retrospective study including 167 patients with metastatic pancreatic cancer (aged ≥70 years and male/female: 78/89) between January 2010 and July 2015. Patients’ retrieved data from medical records were analyzed according to treatment types, followed by a review of clinicopathologic variables and treatment outcomes. <b><i>Results:</i></b> Of the 167 eligible patients for the study, only 21.6% (<i>n</i> = 36) received palliative chemotherapy. The median age of the chemotherapy group was 74.0 years and 78.6 years for the supportive care group. The median survival of the chemotherapy group was 9.2 months (range: 1.0–24.9 months), compared with that of the supportive care group, which was 2.3 months (range: 0.1–31.8 months). Among the patients in the chemotherapy group, 50% (<i>n</i> = 18) received gemcitabine-based double therapy, and 30% patients (<i>n</i> = 9) received second-line chemotherapy. <b><i>Conclusions:</i></b> Our results showed that older patients with metastatic pancreatic cancer were less likely to receive chemotherapy. However, the survival benefit from chemotherapy was comparable to that of younger patients’ counterpart. Thus, further study involving identification of older patients who would benefit from cytotoxic chemotherapy is needed.